View Post

Rare Patient Voice Research opportunity for Squamous Cell Carcinoma (Head and Neck Cancer) patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Details: 20-min pre-work, 75-min web-assisted phone interview Please sign up at the link below to receive an email invite to the survey.  Compensation $160 ($35 for prework, $125 for interview). Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They …

View Post

Rare Patient Voice Research opportunity for Head and Neck Cancer Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Details: 60 min web-assisted phone interview Please sign up at the link below to receive an email invite to the survey.  Compensation $100 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to …

View Post

FDA Grants Breakthrough Therapy Designation for Debiopharm’s Novel Chemo-Radio Sensitizer Debio 1143 for Front-line Treatment of Head & Neck Cancer

In Clinical Studies News by Barbara Jacoby

From: PR Newswire – There have been no newly approved therapies over the last 25 years for “high risk” locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) patients –  The FDA decision was based on the compelling magnitude of the clinically phase II findings in combination with chemo-radiotherapy presented in September 2019 at the ESMO congress (European Society …

View Post

GeneCentric and Collaborators at Washington University Advance Academic-Industry Head and Neck Cancer Partnership under NCI Grant

In Clinical Studies News by Barbara Jacoby

Source: GeneCentric Therapeutics, Inc. From: biospace.com GeneCentric Therapeutics, Inc. today announced that it has entered the second phase of an academic-industry collaboration with Jose Zevallos MD, MPH, Chief of the Division of Head and Neck Oncologic Surgery in the Department of Otolaryngology at Washington University School of Medicine in St. Louis. This collaboration is funded by a National Cancer Institute …

View Post

Every data point has a face: What Michael Becker taught us

In In The News by Barbara Jacoby

By: Matthew Herper From: statnews.com Michael Becker was a biotech executive before he was a patient advocate. When he discovered he had head and neck cancer, he decided to go public, and in doing so made an impact — both within the drug industry and beyond. Cancer, Becker once said, takes away a lot more than it gives. But he …

View Post

Rakuten Medical’s ASP-1929 photoimmunotherapy for head and neck cancers to be designated under the Sakigake Designation System for its potential innovativeness and effectiveness

In Clinical Studies News by Barbara Jacoby

Source: Rakuten Medical, Inc. From: prnewswire.com Based on its exclusive license related to photoimmunotherapy, Rakuten Medical Inc., which is developing a cancer therapy to target cancer cells, announced that ASP-1929 received Sakigake designation under the Sakigake Designation System*, which is a Fast Track designation from the Japanese Ministry of Health, Labour, and Welfare as a treatment for head and neck …

View Post

CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

In Clinical Studies News by Barbara Jacoby

Source: Business Wire From: apnews.com CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The data from all 928 enrolled patients were provided to the …

View Post

Imaging technique finds differences between radiation-sensitive and resistant tumors

In Clinical Studies News by Barbara Jacoby

Source: University of Arkansas From: sciencedaily.com Researchers have started pilot clinical studies in head and neck cancer patients to determine if Raman spectroscopy, a noninvasive imaging technique, can effectively spare some patients of the toxic side effects of ineffective radiation therapy. Researchers at the University of Arkansas, Johns Hopkins University and the University of Arkansas for Medical Sciences (UAMS) used …

View Post

Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor

In Clinical Studies News by Barbara Jacoby

From: prnewswire.com Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor. This marks the second patient with metastatic cancer observed in full remission (complete response) after treatment …

View Post

Study identifies predictors of immunotherapy response in head and neck cancer

In In The News by Barbara Jacoby

Source: Dana-Farber Cancer Institute From: Redington Newsdesk Dana-Farber Cancer Institute scientists say they have identified factors that predict improved response and survival in patients with head and neck cancers treated with checkpoint inhibitor immunotherapy. Two immunotherapy agents known as checkpoint inhibitors have been approved to treat patients whose disease is resistant to standard platinum-based chemotherapy. However, only a minority of …